Herpes zoster - Èpès Zoster
☆ AI Dermatology — Free Service
Nan rezilta Stiftung Warentest 2022 ki soti nan Almay, satisfaksyon konsomatè yo ak ModelDerm te sèlman yon ti kras pi ba pase ak konsiltasyon telemedsin peye.
Nan rezilta Stiftung Warentest 2022 ki soti nan Almay, satisfaksyon konsomatè yo ak ModelDerm te sèlman yon ti kras pi ba pase ak konsiltasyon telemedsin peye.
Herpes zoster ti boul sou kou a ak zepòl
relevance score : -100.0%
ReferencesZona, ki te koze pa reaktivasyon viris varicella‑zoster (varicella‑zoster virus) ki responsab varicella la, afekte anviwon 1 milyon moun chak ane nan peyi Etazini, ak yon risk pou tout lavi 30%. Moun ki gen sistèm iminitè febli yo siyifikativman plis tandans devlope zona, ak sentòm tipikman kòmanse ak malèz, maltèt, ak yon lafyèv ki pa twò grav, ki te swiv pa sansasyon po etranj kèk jou anvan aparans nan yon gratèl. Gratèl sa a, anjeneral parèt nan yon zòn espesifik nan kò a, pwogrese soti nan ti anpoul klè nan maleng kwout sou yon semèn a dis jou. Tretman rapid ak medikaman antiviral (acyclovir, valacyclovir, oswa famciclovir) nan lespas 72 èdtan apre kòmansman gratèl la enpòtan anpil. Neuralji postherpetic, yon konplikasyon komen ki karakterize pa doulè pwolonje nan zòn ki afekte a, afekte apeprè youn nan senk pasyan epi li mande pou jesyon kontinyèl ak medikaman tankou gabapentin, pregabalin, oswa sèten antidepresan, ansanm ak ajan topik tankou lidokayin oswa capsaicin. Yo rekòmande vaksinasyon kont viris varicella‑zoster (varicella‑zoster virus) la pou adilt ki gen laj 50 an oswa pi wo a pou diminye risk pou yo gen zona.
Shingles, caused by the reactivation of the varicella zoster virus responsible for chickenpox, affects around 1 million people annually in the United States, with a lifetime risk of 30%. Those with weakened immune systems are significantly more prone to developing shingles, with symptoms typically starting with malaise, headache, and a mild fever, followed by unusual skin sensations a few days before the appearance of a rash. This rash, usually appearing in a specific area of the body, progresses from clear blisters to crusted sores over a week to ten days. Prompt treatment with antiviral medications (acyclovir, valacyclovir, or famciclovir) within 72 hours of rash onset is crucial. Postherpetic neuralgia, a common complication characterized by prolonged pain in the affected area, affects about one in five patients and requires ongoing management with medications such as gabapentin, pregabalin, or certain antidepressants, along with topical agents like lidocaine or capsaicin. Vaccination against the varicella zoster virus is recommended for adults aged 50 and above to reduce the risk of shingles.
Shingles, caused by the reactivation of the varicella zoster virus responsible for chickenpox, affects around 1 million people annually in the United States, with a lifetime risk of 30%. Those with weakened immune systems are significantly more prone to developing shingles, with symptoms typically starting with malaise, headache, and a mild fever, followed by unusual skin sensations a few days before the appearance of a rash. This rash, usually appearing in a specific area of the body, progresses from clear blisters to crusted sores over a week to ten days. Prompt treatment with antiviral medications (acyclovir, valacyclovir, or famciclovir) within 72 hours of rash onset is crucial. Postherpetic neuralgia, a common complication characterized by prolonged pain in the affected area, affects about one in five patients and requires ongoing management with medications such as gabapentin, pregabalin, or certain antidepressants, along with topical agents like lidocaine or capsaicin. Vaccination against the varicella zoster virus is recommended for adults aged 50 and above to reduce the risk of shingles.
Herpes zoster gen tandans rive pi souvan nan moun ki gen laj 50 an oswa plis, moun ki gen sistèm iminitè febli, ak moun ki pran medikaman imunosuppressant. Li deklanche pa reyaktivasyon viris varicella‑zoster (varicella‑zoster virus) la, menm viris ki lakòz varisèl la. Sentòm tankou lafyèv, doulè, ak gratèl souvan anvan aparans nan gratèl la karakteristik. Konplikasyon ki pi komen se neuralji pòs‑herpes zoster (postherpetic neuralgia), ki se doulè nè ki pèsistan apre gratèl la efase. Faktè risk ak konplikasyon ki asosye ak herpes zoster (herpes zoster) yo varye selon laj, sante iminitè, ak tan inisyasyon tretman an. Vaksinasyon pou moun ki gen laj 60 ak pi wo yo te montre siyifikativman diminye ensidan an nan herpes zoster (herpes zoster) ak neuralji pòs‑herpes zoster (postherpetic neuralgia). Kòmanse medikaman antiviral ak soulaje doulè nan lespas 72 èdtan apre aparisyon gratèl la ka diminye gravite ak konplikasyon herpes zoster (herpes zoster) ak neuralji pòs‑herpes zoster (postherpetic neuralgia).
Herpes zoster tends to occur more frequently in people aged 50 and older, those with weakened immune systems, and those taking immunosuppressant medications. It's triggered by the reactivation of the varicella-zoster virus, the same virus that causes chickenpox. Symptoms like fever, pain, and itching commonly precede the appearance of the characteristic rash. The most common complication is post-herpetic neuralgia, which is persistent nerve pain after the rash clears up. The risk factors and complications associated with herpes zoster vary depending on age, immune health, and timing of treatment initiation. Vaccination for individuals aged 60 and above has been shown to significantly reduce the occurrence of herpes zoster and post-herpetic neuralgia. Starting antiviral medications and pain relievers within 72 hours of rash onset can lessen the severity and complications of herpes zoster and post-herpetic neuralgia.
Herpes zoster tends to occur more frequently in people aged 50 and older, those with weakened immune systems, and those taking immunosuppressant medications. It's triggered by the reactivation of the varicella-zoster virus, the same virus that causes chickenpox. Symptoms like fever, pain, and itching commonly precede the appearance of the characteristic rash. The most common complication is post-herpetic neuralgia, which is persistent nerve pain after the rash clears up. The risk factors and complications associated with herpes zoster vary depending on age, immune health, and timing of treatment initiation. Vaccination for individuals aged 60 and above has been shown to significantly reduce the occurrence of herpes zoster and post-herpetic neuralgia. Starting antiviral medications and pain relievers within 72 hours of rash onset can lessen the severity and complications of herpes zoster and post-herpetic neuralgia.
Esè klinik yo anvan apwobasyon endike ke vaksen zoster vivan travay alantou 50 a 70 %, pandan y ap vaksen rekombinan fè pi byen, sòti nan 90 a 97 %. Nan syans reyèl yo, yo sipòte rezilta esè yo, ki montre ke vaksen zoster vivan se apeprè 46 % efikas, pandan vaksen rekombinan se alantou 85 %.
The pre-licensure clinical trials show the efficacy of the live zoster vaccine to be between 50 and 70% and for the recombinant vaccine to be higher at 90 to 97%. Real-world effectiveness studies, with a follow-up of approximately 10 years, were reviewed in this article. These data corroborated the efficacy studies, with vaccine effectiveness being 46% and 85% for the live and recombinant vaccines, respectively.
The pre-licensure clinical trials show the efficacy of the live zoster vaccine to be between 50 and 70% and for the recombinant vaccine to be higher at 90 to 97%. Real-world effectiveness studies, with a follow-up of approximately 10 years, were reviewed in this article. These data corroborated the efficacy studies, with vaccine effectiveness being 46% and 85% for the live and recombinant vaccines, respectively.
Varisèl (chickenpox), ki rele tou varicella, rezilta nan premye enfeksyon an ak viris la, tipikman rive pandan anfans oswa adolesans. Yon fwa varisèl la geri, viris la ka rete inaktif (andòmi) nan selil nè imen an pou ane oswa dè dekad, apre sa li ka reaktive. Zoster (Herpes zoster) rezilta lè viris varicella andòmi an reaktive. Lè sa a, viris la vwayaje sou kò nè yo nan tèminezon nè ki nan po a, ki pwodui ti anpoul. Pandan yon epidemi Zoster (Herpes zoster), ekspoze a viris varicella yo jwenn nan ti anpoul Zoster (Herpes zoster) ka lakòz varisèl nan yon moun ki poko gen varisèl.
Faktè risk pou reaktivasyon viris andòmi an gen ladan laj fin vye granmoun, fonksyon iminitè pòv, ak varisèl kontrakte anvan 18 mwa. Viris varicella‑zoster pa menm ak viris herpes simplex, byenke tou de fè pati menm fanmi herpesviris.
Vaksen Zoster (Herpes zoster) diminye risk pou Zoster (Herpes zoster) pa 50% a 90%. Li diminye tou pousantaj neuralgia postherpetic, epi, si Zoster (Herpes zoster) rive, gravite li. Si Zoster (Herpes zoster) devlope, medikaman antiviral tankou aciclovir ka diminye gravite a ak dire maladi a si yo kòmanse nan lespas 72 èdtan apre aparans nan gratèl la.
○ Tretman
Si blesi yo pwopaje rapidman, al wè doktè ou pi vit posib pou tretman antiviral.
Yo mande tou de medikaman antiviral ak medikaman pou neuralgia. Ou ta dwe repoze epi sispann bwè alkòl.
#Acyclovir
#Famciclovir
#Valacyclovir
#Gabapentin
#Pregabalin